BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Price Target Cut to $25.00 by Analysts at JPMorgan Chase & Co.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) had its target price cut by JPMorgan Chase & Co. from $27.00 to $25.00 in a report released on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 172.12% from the stock’s previous close.

Several other research firms have also recently commented on BBOT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research report on Thursday, June 18th. UBS Group downgraded shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. Oppenheimer assumed coverage on BridgeBio Oncology Therapeutics in a research report on Monday, June 22nd. They set an “outperform” rating and a $22.00 price objective on the stock. Wall Street Zen upgraded BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Canaccord Genuity Group initiated coverage on BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $23.00 target price for the company. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.40.

BridgeBio Oncology Therapeutics Stock Down 0.5%

Shares of BridgeBio Oncology Therapeutics stock traded down $0.04 during trading on Friday, reaching $9.19. 69,585 shares of the stock were exchanged, compared to its average volume of 358,610. The firm has a market cap of $736.52 million, a price-to-earnings ratio of -3.33 and a beta of 0.36. BridgeBio Oncology Therapeutics has a 1 year low of $7.00 and a 1 year high of $14.87. The stock’s fifty day moving average is $8.27 and its 200 day moving average is $9.08.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) earnings per share for the quarter. Equities analysts forecast that BridgeBio Oncology Therapeutics will post -2.3 earnings per share for the current year.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BBOT. Paradigm Biocapital Advisors LP boosted its stake in BridgeBio Oncology Therapeutics by 21.2% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock valued at $28,317,000 after purchasing an additional 395,608 shares during the last quarter. Laurion Capital Management LP boosted its position in shares of BridgeBio Oncology Therapeutics by 40.1% during the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock valued at $18,341,000 after buying an additional 419,138 shares during the last quarter. Armistice Capital LLC boosted its position in shares of BridgeBio Oncology Therapeutics by 142.7% during the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after buying an additional 588,000 shares during the last quarter. Geode Capital Management LLC increased its holdings in BridgeBio Oncology Therapeutics by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock worth $7,039,000 after buying an additional 20,385 shares in the last quarter. Finally, Catalio Capital Management LP bought a new stake in BridgeBio Oncology Therapeutics in the 4th quarter worth about $5,142,000. 54.89% of the stock is owned by institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.